Target intelligence / Profile preview

Endoplasmic reticulum oxidoreductase 1 beta (ERO1B)

Target
ERO1B
Molecular classification
Enzyme, Oxidoreductase
01

Overview

Endoplasmic reticulum oxidoreductase 1 beta (ERO1B) is an endoplasmic reticulum-resident oxidoreductase enzyme that catalyzes the formation of protein disulfide bonds, particularly in the folding of nascent polypeptides. ERO1B efficiently reoxidizes protein disulfide isomerase (PDI), enabling continuous rounds of disulfide bond formation essential for proper protein folding. The enzyme uses flavin adenine dinucleotide (FAD) as a cofactor to relay electrons from PDI to molecular oxygen, thus producing hydrogen peroxide (H~2~O~2~) as a byproduct, which may contribute to intracellular reactive oxygen species generation. ERO1B is selectively and highly expressed in pancreatic and stomach tissues, where it is implicated in insulin biogenesis and glucose regulation. Dysregulation or overexpression of ERO1B and its paralog ERO1A are linked to diseases such as diabetes and cancer due to their roles in protein folding stress, cell migration, and apoptosis. The activity of ERO1B is tightly regulated to maintain cellular homeostasis and avoid harmful accumulation of oxidative species.

Other names
ERO1-like protein betaERO1LBERO1-L-betaERO1-L(beta)Ero1betaEndoplasmic reticulum oxidoreductase betaEndoplasmic reticulum oxidoreductin-1-like protein BOxidoreductin-1-L-beta
02

Mechanism of action

Inhibition of oxidative protein folding by blocking electron transfer from ERO1B to molecular oxygen; Targeting interaction with protein disulfide isomerase (PDI) to disrupt disulfide bond formation.

03

Biological functions

Disulfide bond formationProtein foldingOxidative protein folding in the endoplasmic reticulumRegulation of redox stateGlucose homeostasis
04

Disease associations

DiabetesCancerCataractHypoascorbemia
05

Safety considerations

Potential for increased reactive oxygen species (ROS) production leading to oxidative stress and apoptosis if activity is unregulatedEvidence for tight regulation is necessary to avoid cellular damage; redundant pathways (such as PRDX4, GPx8) may compensate in knockout models
06

Interacting drugs

None confirmed or clinically established for ERO1B directly; research and development of ERO1 inhibitors is ongoing, with selective inhibitors primarily targeting the related isoform ERO1A.
07

Biomarkers

Upregulation in pancreatic tissue may serve as a marker in diabetes researchPotential biomarker for certain cancers, suggested by paralog studies involving ERO1A

Beyond the preview

Go deeper on Endoplasmic reticulum oxidoreductase 1 beta (ERO1B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endoplasmic reticulum oxidoreductase 1 beta (ERO1B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call